[Thromboxane A2 synthetase inhibitor in asthma therapy].
Thromboxane A2(TXA2), a platelet aggregator and vasoconstricter, has been implicated as a potential mediator of bronchial asthma. TXA2 induces potent contraction of airway smooth muscles and airway hyperresponsiveness. OKY-046 (ozagrel hydrochloride) is a specific inhibitor of TXA2 synthetase and a new antiasthmatic agent. In a phase III study ozagrel has shown significantly higher effect in ameliorating the asthma symptoms and reduced the dose of concomitant steroid therapy compared to azelastine hydrochloride. Both basical and clinical studies showed that TXA2 synthetase inhibitor is effective on airway hyperresponsiveness. In this review the role of TXA2 synthetase inhibitor in current asthma therapy, which is based on the Japanese guideline of allergic disorders, was discussed.
Machida
K
K
2nd Department of Internal Medicine, Nagoya University School of Medicine.
Takagi
K
K
Horiba
M
M
D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D016535:Bronchial Hyperreactivity; D002986:Clinical Trials as Topic; D006801:Humans; D008689:Methacrylates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013928:Thromboxane A2 / Q000502:physiology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D008689:Methacrylates; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase; C034364:ozagrel